BTAI
Income statement / Annual
Last year (2024), BioXcel Therapeutics, Inc.'s total revenue was $2.27 M,
an increase of 64.20% from the previous year.
In 2024, BioXcel Therapeutics, Inc.'s net income was -$59.60 M.
See BioXcel Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$2.27 M |
$1.38 M |
$375.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.14 M
|
$1.26 M
|
$20.00 K
|
$297.00 K
|
$0.00
|
$156.00 K
|
$17.00 K
|
$1.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$123.00 K
|
$120.00 K
|
$355.00 K
|
-$297.00 K
|
$0.00
|
-$156.00 K
|
-$17.00 K
|
-$1.00 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.05
|
0.09
|
0.95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$30.44 M
|
$84.33 M
|
$91.24 M
|
$51.59 M
|
$58.54 M
|
$25.80 M
|
$14.56 M
|
$2.69 M
|
$1.40 M
|
$233.00 K
|
| General & Administrative Expenses |
$33.10 M
|
$63.51 M
|
$55.76 M
|
$0.00
|
$24.30 M
|
$7.80 M
|
$5.40 M
|
$1.85 M
|
$721.00 K
|
$0.00
|
| Selling & Marketing Expenses |
$1.39 M
|
$19.90 M
|
$13.01 M
|
$0.00
|
$345.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$34.49 M
|
$83.41 M
|
$68.76 M
|
$54.01 M
|
$24.65 M
|
$7.80 M
|
$5.40 M
|
$1.85 M
|
$721.00 K
|
$403.00 K
|
| Other Expenses |
$2.44 M
|
$4.16 M
|
$0.00
|
$0.00
|
-$888.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$67.37 M
|
$171.90 M
|
$160.00 M
|
$105.60 M
|
$82.30 M
|
$33.60 M
|
$19.96 M
|
$4.54 M
|
$2.12 M
|
$636.00 K
|
| Cost And Expenses |
$69.51 M
|
$173.16 M
|
$160.02 M
|
$105.90 M
|
$82.30 M
|
$33.60 M
|
$19.96 M
|
$4.54 M
|
$2.12 M
|
$636.00 K
|
| Interest Income |
$2.60 M
|
$5.65 M
|
$2.53 M
|
$4.00 K
|
$155.00 K
|
$633.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$15.13 M
|
$13.31 M
|
$8.21 M
|
$40.00 K
|
$27.00 K
|
$0.00
|
$0.00
|
$2.00 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$309.00 K
|
$318.00 K
|
$327.00 K
|
$297.00 K
|
$188.00 K
|
$156.00 K
|
$17.00 K
|
$1.00 K
|
$2.12 M
|
$0.00
|
| EBITDA |
-$44.16 M |
-$165.42 M |
-$157.22 M |
-$107.00 M |
-$82.11 M |
-$32.81 M |
-$19.25 M |
-$4.54 M |
$0.00 |
-$636.00 K |
| EBITDA Ratio |
-19.49
|
-119.87
|
-419.25
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-29.68
|
-124.48
|
-425.72
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$7.65 M
|
-$7.27 M
|
-$6.11 M
|
-$1.40 M
|
$128.00 K
|
$633.00 K
|
$692.00 K
|
-$2.00 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$59.60 M
|
-$179.05 M
|
-$165.76 M
|
-$107.29 M
|
-$82.17 M
|
-$32.97 M
|
-$19.27 M
|
-$4.54 M
|
-$2.12 M
|
-$636.00 K
|
| Income Before Tax Ratio |
-26.3
|
-129.75
|
-442.02
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
-$362.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$59.60 M
|
-$179.05 M
|
-$165.76 M
|
-$106.93 M
|
-$82.17 M
|
-$32.34 M
|
-$19.27 M
|
-$4.54 M
|
-$2.12 M
|
-$636.00 K
|
| Net Income Ratio |
-26.3
|
-129.75
|
-442.02
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-23.51 |
-98.35 |
-94.67 |
-64.87 |
-60.63 |
-32.38 |
-21.16 |
-4.41 |
-2.06 |
-0.64 |
| EPS Diluted |
-23.51 |
-98.35 |
-94.67 |
-64.87 |
-60.63 |
-32.38 |
-21.16 |
-4.41 |
-2.06 |
-0.64 |
| Weighted Average Shares Out |
$2.54 M
|
$1.82 M
|
$1.75 M
|
$1.65 M
|
$1.36 M
|
$1.02 M
|
$910.72 K
|
$1.03 M
|
$1.03 M
|
$996.31 K
|
| Weighted Average Shares Out Diluted |
$2.54 M
|
$1.82 M
|
$1.75 M
|
$1.65 M
|
$1.36 M
|
$1.02 M
|
$910.72 K
|
$1.03 M
|
$1.03 M
|
$996.31 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
